ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in various dosages. This launch expands the company's injectable portfolio and presence in the U.S. hospital market.
Glenmark Pharmaceuticals launched Sugammadex Injection in the U.S. market. This addition strengthens the company's injectable portfolio and presence in the hospital segment.
Glenmark advanced its Phase 3 trial for Trastuzumab rezetecan in ovarian cancer. India is first to enroll, with plans for Australia and South Korea pending approvals.
Glenmark Pharmaceuticals launched Lacosamide Injection USP in the United States. This expansion of their injectable portfolio targets a market with $15.2 million in annual sales.
Glenmark launched Vancomycin Hydrochloride for Injection in the U.S. market. The product targets a ₹363.84 Crore market, strengthening the company's injectable portfolio and presence.